← Companies|Alkermes
AL

Alkermes

ALKS·NASDAQDublin IEFounded 19872,200 employees
Mid CapbiotechPublicCNS
Platform: Lybalvi CNS
Market Cap
$5B
All Drugs
3
Clinical Trials
7
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (ALKS)
Loading ALKS stock data...
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
GelicilimabALK-6499Phase 34NanobodyPD-1PD-L1iUCHuntington's
ALK-5502ALK-5502Phase 11mAbPLK4BETiHuntington's
ALK-4522ALK-4522Phase 12DegraderWRNCDK4/6iHS
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (7)
2026-07-15
ALK-4522 Interim
HS
Interim
2028-05-24
ALK-4522 Interim
HS
Interim
2028-06-01
ALK-5502 Interim
Huntington's
Interim
2028-11-10
Gelicilimab Ph3 Readout
Huntington's
Ph3 Readout
2029-07-24
Gelicilimab Ph3 Readout
UC
Ph3 Readout
2030-01-27
Gelicilimab Ph3 Readout
UC
Ph3 Readout
2031-09-25
Gelicilimab Ph3 Readout
Huntington's
Ph3 Readout